The concomitant use of sodium-glucose co-transporter 2 inhibitors improved the renal outcome of Japanese patients with type 2 diabetes treated with glucagon-like peptide 1 receptor agonists.

Abstract

Aims:

This study aimed to clarify the renal influence of glucagon-like peptide 1 receptor agonists (GLP1Ras) with or without sodium-glucose co-transporter 2 inhibitors (SGLT2is) on Japanese patients with type 2 diabetes mellitus (T2DM).

Methods:

We retrospectively extracted 547 patients with T2DM who visited the clinics of members of Kanagawa Physicians Association. The progression of albuminuria status and/or a ≥ 15% decrease in the estimated glomerular filtration rate (eGFR) per year was set as the renal composite outcome. Propensity score matching was performed to compare GLP1Ra-treated patients with and without SGLT2i.

Results:

After matching, 186 patients in each group were compared. There was no significant difference of the incidence of the renal composite outcomes (17% vs. 20%, P = 0.50); however, the annual decrease in the eGFR was significantly smaller and the decrease in the urine albumin-to-creatinine ratio was larger in GLP1Ra-treated patients with the concomitant use of SGLT2is than in those without it (-1.1 ± 5.0 vs. -2.8 ± 5.1 mL/min/1.73 m2, P = 0.001; and -0.08 ± 0.61 vs. 0.05 ± 0.52, P = 0.03, respectively).

Conclusion:

The concomitant use of SGLT2i with GLP1Ra improved the annual decrease in the eGFR and the urine albumin-to-creatinine ratio in Japanese patients with T2DM.

• Authors: Kazuo Kobayashi, Masao Toyoda, Nobuo Hatori, Shunichiro Tsukamoto, Moritsugu Kimura, Hiroyuki Sakai, Takayuki Furuki, Keiichi Chin, Tomohiko Kanaoka, Togo Aoyama, Tomoya Umezono, Shun Ito, Daisuke Suzuki, Hiroshi Takeda, Hisakazu Degawa, Toshimasa Hishiki, Hidetoshi Shimura, Shinichi Nakajima, Masaaki Miyauchi, Hareaki Yamamoto, Yutaka Hatori, Masahiro Hayashi, Kazuyoshi Sato, Masaaki Miyakawa, Yasuo Terauchi, Kouichi Tamura, Akira Kanamori
• Journal: Cardiovascular endocrinology & metabolism (Cardiovasc Endocrinol Metab) Vol. 12 Issue 4 Pg. e0292 (Dec 2023) ISSN: 2574-0954 [Electronic] United States
• PMID: 37779602 (Publication Type: Journal Article)
• Copyright: Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.